Technical Analysis for WENA - Anew Medical, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -27.42% | |
| Narrow Range Bar | Range Contraction | -27.42% | |
| Wide Bands | Range Expansion | -27.42% | |
| Calm After Storm | Range Contraction | -40.00% | |
| Wide Bands | Range Expansion | -40.00% | |
| Oversold Stochastic | Weakness | -40.00% |
| Alert | Time |
|---|---|
| Down 5% | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| Down 1% | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: Unknown
Anew Medical, Inc Description
Anew Medical, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It operates through the following segments: Generic Drugs, Gene Therapy, and Pharmaceutical Programs. The Generic Drugs segment consists of portfolio of drugs and biosimilar biologics selling hard-to-source, difficult to find generic drugs and off-patent biologic therapies, and proprietary and patented technology platforms that include a library of melanocortin receptor-binding molecules. The Gene Therapy segment focuses on the gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging. The Pharmaceutical Programs segment includes treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The company was founded on August 2, 2004 and is headquartered in Omaha, NE.
Classification
Sector: Financial Services
Industry: Shell Companies
Keywords: Biopharmaceutical Disease Medication Gene Therapy Neurodegenerative Diseases Biosimilar Generic Drug Biologic Therapies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.1 |
| 52 Week Low | 1.54 |
| Average Volume | 2,149,483 |
| 200-Day Moving Average | 9.41 |
| 50-Day Moving Average | 5.82 |
| 20-Day Moving Average | 4.74 |
| 10-Day Moving Average | 3.43 |
| Average True Range | 1.08 |
| RSI (14) | 32.89 |
| ADX | 22.46 |
| +DI | 29.34 |
| -DI | 33.51 |
| Chandelier Exit (Long, 3 ATRs) | 4.88 |
| Chandelier Exit (Short, 3 ATRs) | 4.77 |
| Upper Bollinger Bands | 8.35 |
| Lower Bollinger Band | 1.14 |
| Percent B (%b) | 0.09 |
| BandWidth | 152.01 |
| MACD Line | -1.12 |
| MACD Signal Line | -0.82 |
| MACD Histogram | -0.291 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.02 | ||||
| Resistance 3 (R3) | 3.11 | 2.81 | 2.81 | ||
| Resistance 2 (R2) | 2.81 | 2.50 | 2.76 | 2.74 | |
| Resistance 1 (R1) | 2.30 | 2.31 | 2.15 | 2.21 | 2.68 |
| Pivot Point | 2.00 | 2.00 | 1.92 | 1.95 | 2.00 |
| Support 1 (S1) | 1.49 | 1.69 | 1.34 | 1.40 | 0.92 |
| Support 2 (S2) | 1.19 | 1.50 | 1.14 | 0.86 | |
| Support 3 (S3) | 0.68 | 1.19 | 0.79 | ||
| Support 4 (S4) | 0.59 |
